Cancers, Volume 15, Issue 3
2023 February-1 - 439 articles
Cover Story: Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor inhibitor receptor (VEGFR) inhibitors are currently both acceptable options for patients with treatment-naïve advanced papillary renal cell carcinoma (pRCC). ICI combinations—either with VEGFR or with MET inhibitors—are also promising therapeutic strategies. Several ongoing trials in this setting will help to clarify the optimal approach for the treatment of advanced pRCC. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.